Coherus BioSciences (FRA:8C5) EV-to-EBIT : -24.09 (As of May. 29, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Coherus BioSciences's Enterprise Value is €402.4 Mil. Coherus BioSciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-16.7 Mil. Therefore, Coherus BioSciences's EV-to-EBIT for today is -24.09.

The historical rank and industry rank for Coherus BioSciences's EV-to-EBIT or its related term are showing as below:

FRA:8C5' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.7 Med: -3.95 Max: 373.64
Current: -24.63

During the past 12 years, the highest EV-to-EBIT of Coherus BioSciences was 373.64. The lowest was -29.70. And the median was -3.95.

FRA:8C5's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.85 vs FRA:8C5: -24.63

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Coherus BioSciences's Enterprise Value for the quarter that ended in Mar. 2024 was €453.4 Mil. Coherus BioSciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-16.7 Mil. Coherus BioSciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -3.68%.

Coherus BioSciences EV-to-EBIT Historical Data

The historical data trend for Coherus BioSciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences EV-to-EBIT Chart

Coherus BioSciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

11.58

7.24

-4.66

-3.52

-3.73

Coherus BioSciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-3.79	-3.24	-4.24	-3.73	-27.80

Competitive Comparison of Coherus BioSciences's EV-to-EBIT

For the Biotechnology subindustry, Coherus BioSciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus BioSciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's EV-to-EBIT falls into.

Coherus BioSciences EV-to-EBIT Calculation

Coherus BioSciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	402.413	/	-16.702
	=	-24.09

Coherus BioSciences's current Enterprise Value is €402.4 Mil.
Coherus BioSciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.7 Mil.

Coherus BioSciences (FRA:8C5) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Coherus BioSciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-16.702	/	453.3704
	=	-3.68 %

Coherus BioSciences's Enterprise Value for the quarter that ended in Mar. 2024 was €453.4 Mil.
Coherus BioSciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.7 Mil.

Coherus BioSciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Coherus BioSciences (FRA:8C5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

CHRS:USA

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Coherus BioSciences (FRA:8C5) Headlines

No Headlines